Comparative Pharmacology
Head-to-head clinical analysis: INTELENCE versus RESCRIPTOR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: INTELENCE versus RESCRIPTOR.
INTELENCE vs RESCRIPTOR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Non-nucleoside reverse transcriptase inhibitor (NNRTI). Binds directly to HIV-1 reverse transcriptase, causing allosteric inhibition of RNA-dependent and DNA-dependent DNA polymerase activities.
Non-nucleoside reverse transcriptase inhibitor (NNRTI) that binds directly to HIV-1 reverse transcriptase, causing conformational change and inhibiting RNA-dependent DNA polymerase activity.
200 mg orally twice daily after a meal.
400 mg orally three times daily.
None Documented
None Documented
Terminal elimination half-life is approximately 40 hours (range 30-60 hours). This supports once-daily dosing with 400 mg (two 200 mg tablets) after initial twice-daily dosing for 2 weeks, but note that etravirine is only approved for twice-daily dosing (200 mg twice daily) in treatment-experienced patients.
Terminal elimination half-life is 2.5–4.5 hours in adults. This short half-life necessitates twice-daily dosing. In patients with hepatic impairment, half-life may be prolonged.
Primarily fecal (76.6% as unchanged drug or metabolites) with minor renal excretion (19.6%, of which 1.2% is unchanged). Biliary elimination of metabolites may occur.
Renal: 51% (unchanged drug) and 44% (glucuronide metabolite); biliary/fecal: <5%. Total recovery in urine is approximately 95%.
Category C
Category C
NNRTI Antiretroviral
NNRTI Antiretroviral